|13th August 2020||Bradley S Hargreaves||1,234,855||Exercise of derivative||$0.05||$61,742.75|
|13th August 2020||Jean M Arnett||1,250,000||Exercise of derivative||$0.05||$62,500.00|
|30th July 2020||Frank Mcenulty||40,000||Open or private purchase||$0.25||$10,000.00|
|28th April 2020||Richard Jeffs||1,665||Open or private sale||$0.60||$999.00|
|27th April 2020||Richard Jeffs||15,607||Open or private sale||$0.60||$9,364.20|
|24th April 2020||Richard Jeffs||5,500||Open or private purchase||$0.42||$2,332.00|
|21st April 2020||Richard Jeffs||1,000,000||Open or private purchase||$0.15||$150,000.00|
|16th April 2020||Richard Jeffs||5,000||Open or private purchase||$0.32||$1,600.00|
|15th April 2020||Richard Jeffs||5,000||Open or private purchase||$0.33||$1,650.00|
|15th April 2020||Richard Jeffs||5,000||Open or private purchase||$0.33||$1,648.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 5/10.
Cell MedX Corp. was founded on March 19, 2010 and is headquartered in Carson City, NV. Its products include electromedical technology, and ebalance technology for diabetes and related complications.